Home » Stocks » AXLA

Axcella Health, Inc. (AXLA)

Stock Price: $3.36 USD 0.03 (0.90%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 126.75M
Revenue (ttm) n/a
Net Income (ttm) -56.71M
Shares Out 37.72M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $3.36
Previous Close $3.33
Change ($) 0.03
Change (%) 0.90%
Day's Open 3.36
Day's Range 3.30 - 3.48
Day's Volume 73,503
52-Week Range 3.12 - 6.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

5 days ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

2 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

3 weeks ago - Business Wire

Axcella Health Inc (NASDAQ: AXLA) is a clinical-stage biotechnology company focused on endogenous metabolic modulators, or EEMs, said Axcella Health CEO Bill Hinshaw Thursday on Benzinga's YouTube show ...

1 month ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulat...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

2 months ago - Business Wire

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

Other stocks mentioned: CDAK, DNLI, EVLO, FHTX, KLDO, MCRB, MRNA ...
2 months ago - PRNewsWire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

4 months ago - Business Wire

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CTMX, KLDO, MGTA
4 months ago - 24/7 Wall Street

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

6 months ago - Business Wire

Axcella Health Inc. (AXLA) CEO Bill Hinshaw on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

6 months ago - Business Wire

Axcella (AXLA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modula...

7 months ago - Business Wire

--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases a...

7 months ago - Business Wire

Axcella Health (AXLA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

Axcella Health Inc. (AXLA) CEO Bill Hinshaw on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating comp...

9 months ago - Business Wire

Axcella AXLA) will provide updates on its clinical programs when it releases second-quarter 2020 results.

9 months ago - Zacks Investment Research

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CTMX, KLDO, MGTA
9 months ago - 24/7 Wall Street

Is (AXLA) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

Axcella Health (AXLA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

If you’re looking to hedge against a coming pullback in the markets, we've used our deep learning algorithms and AI to identify the Top Shorts today.

Other stocks mentioned: AGEN, ATOM, EYPT, MGEN
10 months ago - Forbes

Axcella Health Inc. (AXLA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

10 months ago - Zacks Investment Research

Is (AXLA) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

An alarming rise in the number of coronavirus cases results in volatility in the market and raises the appeal of defensive stocks

Other stocks mentioned: ABBV, AWR, BGS, CLX
11 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor of Axcella Health

11 months ago - Zacks Investment Research

The stock market’s fall from February through March was monumental, bringing on the fastest bear market we have seen in our lives.

Other stocks mentioned: FLY, FMCC, FNMA, GLOG, GPP, PGEN, SNCR ...
11 months ago - 24/7 Wall Street

Axcella Health (NASDAQ: AXLA) shares are trading higher on Thursday, after Wedbush initiated coverage on the stock with an Outperform rating and announced a price target of $28 per share.

11 months ago - Benzinga

Axcella Health Inc (NASDAQ: AXLA) shares were soaring Wednesday following a clinical readout from the company.

1 year ago - Benzinga

Axcella Health Inc. (AXLA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

Axcella Health: Rough Sledding, But Still In The Game

1 year ago - Seeking Alpha

Liver Therapy Forum weekly digest provides an overview on therapeutics in development for hepatic encephalopathy in 2019. The focus this week is on Axcella Health.

1 year ago - Seeking Alpha

About AXLA

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. It also develops AXA4010, a hematology product candidate; and AXA2678, a muscle product candidate. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in J... [Read more...]

Industry
Biotechnology
IPO Date
May 9, 2019
Stock Exchange
NASDAQ
Ticker Symbol
AXLA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Axcella Health stock is "Buy." The 12-month stock price forecast is 15.22, which is an increase of 352.98% from the latest price.

Price Target
$15.22
(352.98% upside)
Analyst Consensus: Buy